Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2018-03-14 Earnings Release
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Earnings Release Classification · 1% confidence The document is titled "Onxeo présente un point d'étape financier" (Onxeo presents a financial update) and details a significant accounting adjustment (a €38M asset impairment charge related to Beleodaq®) recognized in the 2017 consolidated accounts under IFRS standards. It discusses financial performance contextually, mentions the upcoming publication of the full 2017 annual results, and provides operational updates (AsiDNA™ clinical trial). This content—a detailed financial update focusing on specific accounting treatments and operational milestones outside of a full annual report or a standard earnings release—is characteristic of a Management Discussion and Analysis (MDA) or a detailed interim report. Since it is a specific update on financial performance and business trends leading up to the final annual report publication, it aligns best with the Management Reports (MDA) definition, which covers management's explanation of financial results and business trends. It is not a full 10-K, a brief ER, or a formal AR/Audit Report. FY 2017
2018-03-14 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Investor Presentation Classification · 1% confidence The document is a press release dated January 25, 2018, announcing that Onxeo received a notification from the European Patent Office (OEB) of its intention to grant a key patent covering AsiDNA™. The content focuses on intellectual property protection, patent expiry dates, and the scientific mechanism of the drug candidate. This type of announcement, which details specific legal/IP developments outside of standard financial reporting (like 10-K or ER), is best classified as a general regulatory or corporate announcement. Since it is not a formal financial report, a management change, a dividend notice, or a specific legal proceeding update, and it is a direct communication about a corporate asset (IP), it fits best under the general 'Regulatory Filings' (RNS) category as a significant, non-standard corporate update, or potentially 'LTR' if viewed as a legal/IP development, but RNS is the broader fit for press releases detailing specific corporate actions/developments not covered elsewhere. Given the focus on patent grant notification, 'LTR' (Legal Proceedings Report) might seem plausible, but RNS is often used for general regulatory news releases. However, since the core subject is the granting of a patent, which is a form of legal protection/asset update, and it is not a standard financial filing, I will check if there is a better fit. None of the other codes (AGM-R, 10-K, ER, MANG, DIV, etc.) apply. 'LTR' covers 'significant lawsuits, regulatory actions, or legal matters'. A patent grant notification is a positive legal/regulatory event. Given the specific nature of the IP news, 'LTR' is a strong candidate, but 'RNS' is the catch-all. Since the document is a press release detailing a specific legal/IP development (patent grant), and 'LTR' covers 'legal matters', I will lean towards 'LTR' as it is more specific than the general 'RNS' fallback, although RNS is also defensible for any press release. Re-evaluating the definitions: LTR is for proceedings/lawsuits. This is a patent grant notification. Therefore, RNS (General regulatory announcements and fallback category) is the most appropriate classification for this specific type of corporate news release that doesn't fit the other specific categories.
2018-01-25 French
Communicated under the obligation to provide permanent information / Other communications
Investor Presentation Classification · 1% confidence The document is an announcement dated January 25, 2018, detailing that Onxeo S.A. received an Intent-to-Grant Notice from the European Patent Office (EPO) for a key patent covering AsiDNA™. The content focuses entirely on intellectual property protection, patent terms, and the scientific mechanism of the drug candidate. This is a specific update regarding the company's IP portfolio, which falls under the general category of investor/corporate information, but is not a comprehensive financial report (10-K, IR), a management change (MANG), or a dividend notice (DIV). Since it is a specific announcement about a legal/IP asset extension, and there is no specific code for 'Intellectual Property Announcement', the closest fit among the provided options that deals with specific corporate assets or legal matters is either LTR (Legal Proceedings Report, which is usually negative/litigation) or RNS (Regulatory Filings/General Announcement). Given the focus on patent grant intent, which is a significant corporate development but not a standard financial filing, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback, although IP-related announcements often fall here if a dedicated code is missing. However, upon reviewing the definitions, the document is essentially an update on a key asset's protection, which is a form of corporate news. Since it is not a standard financial report, earnings release, or management change, RNS serves as the best general regulatory/corporate announcement category.
2018-01-25 English
Communicated under the obligation to provide permanent information / Other communications
Legal Proceedings Report Classification · 1% confidence The document text is a press release dated January 23, 2018, providing an update on ongoing litigation ('litigation with SpeBio/SpePharm') and mentioning future financial reporting dates ('2017 annual results: Thursday March 29, 2018'). The content focuses on legal proceedings and business updates rather than releasing full financial statements, announcing management changes, or soliciting votes. Since it specifically details an update on a significant lawsuit, it fits the description of a Legal Proceedings Report (LTR). It is not a full financial report (10-K or IR), nor is it a general regulatory announcement (RNS) as it addresses a specific legal matter.
2018-01-23 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Legal Proceedings Report Classification · 1% confidence The document is a press release dated January 23, 2018, detailing an update on a legal dispute ('litige') and providing a forward-looking statement about the upcoming release of the 2017 annual results ('Résultats annuels 2017'). It is not the full Annual Report (10-K), nor is it the comprehensive Interim Report (IR). It is a specific announcement regarding legal proceedings and future financial reporting dates. The content focuses heavily on the legal update ('litige avec SpeBio/SpePharm') and the company pipeline/business overview, which is typical of a general press release or regulatory update. Since it specifically discusses a significant legal matter ('litige au fond'), the most fitting category is Legal Proceedings Report (LTR). It is too detailed for a simple Report Publication Announcement (RPA) as it contains substantive business updates, not just a notice of publication.
2018-01-23 French
Communicated under the obligation to provide permanent information / Other communications
Report Publication Announcement Classification · 1% confidence The document is titled "Onxeo Announces its Financial Agenda for 2018" and explicitly lists the dates for future financial events like 'Full-year 2017 results', 'Q1 2018 financial information', and 'Half-year 2018 results'. This is not the actual financial report (like 10-K or IR), but rather an announcement about *when* those reports and other key events (like the AGM) will be released. Since it is an announcement detailing the schedule for future report publications, it fits the definition of a Report Publication Announcement (RPA). The document length (4216 chars) is short enough to support this classification based on the 'MENU VS MEAL' rule, as it is announcing the publication rather than containing the full substance of the reports themselves.
2018-01-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.